Ustekinumab vs placebo
Failure to induce clinical response (6 mg/kg subgroup) CDAI (≥100 point reduction) · induction of remission in Crohn's disease
Ustekinumab leads to lower failure to induce clinical response (6 mg/kg subgroup) CDAI (≥100… compared with placebo (high certainty).
1 finding from 1 review
- Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 0.83 [0.77, 0.91]2 studies · 916 participantsHigh